Table 3.
Patients characteristics and antihyperglycemic agents associated with LVEF.
| Odds Ratio (95% CI) | |||
|---|---|---|---|
| HFpEF | HFmrEF | HFrEF | |
| Model 1 | |||
| Male Sex | Reference | 4.40 (1.59–12.20) | 2.71 (1.22–6.00) |
| Model 2 | |||
| Sulphonylurea | Reference | 1.18(0.56–2.47) | 2.42 (1.23–4.79) |
| Model 3 | |||
| Male Sex | Reference | 4.40 (1.58–12.25) | 2.51 (1.11–5.66) |
| Sulphonylurea | Reference | 1.04 (0.48–2.23) | 2.22 (1.11–4.45) |
| Age | Reference | 0.99 (0.96–1.03) | 0.98 (0.95–1.01) |
| Model 4 | |||
| Male Sex | Reference | 4.78 (1.69–13.50) | 2.35 (1.03–5.39) |
| Sulphonylurea | Reference | 1.07 (0.49–2.30) | 2.17 (1.08–4.36) |
| Age | Reference | 0.99(0.97–1.03) | 0.98 (0.95–1.01) |
| HbA1c | Reference | 1.11 (0.93–1.31) | 0.94 (0.79–1.11) |
Computed by Multinomial Logistic Regression; bolded font indicates statistical significance at p < 0.05. CI, confidence interval; HbA1C, glycated hemoglobin; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.